Source: DGNews  |  Posted 8 years ago

INDIANAPOLIS, IN -- December 30, 2003 -- Eli Lilly and Company (NYSE:LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Symbyax(TM) (olanzapine and fluoxetine HCl) for the treatment of depressive episodes associated with bipolar disorder. Symbyax (pronounced SIMM-bee-ax), which is a combination of olanzapine, the active ingredient in Zyprexa